¿Cuál es el fundamento de las terapias basadas en la utilización de células t modificadas (car- t-cells)?

Article Sidebar

PDF (Spanish)
Published: 2018-09-30
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v38i3.569

Main Article Content

Aída E. Sterin Prync
Profesora Titular de Biotecnología, Carrera de Bioquímica. Departamento de Bioquímica Aplicada. Instituto Universitario del Hospital Italiano

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 38 No. 3 (2018): Revista del Hospital Italiano de Buenos Aires

Section

Ask the expert
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
Sterin Prync AE. ¿Cuál es el fundamento de las terapias basadas en la utilización de células t modificadas (car- t-cells)?. Rev Hosp Ital B.Aires [Internet]. 2018 Sep. 30 [cited 2026 Apr. 27];38(3):119-21. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/569

References

Billingham RE, Brent L, Medawar PB. Quantitative Studies on Tissue Transplantation Immunity. II. The Origin, Strength and Duration of Actively and Adoptively Acquired Immunity. Proc R Soc London. 1954; 143(910):58-80. DOI: https://doi.org/10.1098/rspb.1954.0054

Smyth MJ. Multiple approaches to immunotherapy - the new pillar of cancer treatment. Immunol Cell Biol. 2017; 95(4):323-324. DOI: https://doi.org/10.1038/icb.2017.9

Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507–17. DOI: https://doi.org/10.1056/NEJMoa1407222

Brentjens RJ, Davila ML, Riviere I, et al. D19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. DOI: https://doi.org/10.1126/scitranslmed.3005930

Tran E, Longo DL, Urba WJ, et al. A Milestone for CAR T Cells. N Engl J Med 2017; 377:2593-2596 DOI: https://doi.org/10.1056/NEJMe1714680